Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implications – PubMed
A new subgroup at risk
Related Articles
Predicting CKD Outcomes in Lupus Nephritis | RheumNow
An observational cohort study suggests that proteinuria levels in lupus nephritis (LN) patients did not predict their histologic class. A multicentre observational study of patients…
How Twisters’ Director Developed a Taste for Disaster
Lee Isaac Chung revealed how a scene in his previous movie, Minari, inspired the tornado sequel.
Uveitis History Linked to Recurrence After COVID Vaccination
Commentators say it’s important to keep findings in perspective in light of vaccine benefits
Connecting with Other Parents May Ease Parental Loneliness for Many
Many parents experience high levels of isolation, loneliness, and burnout, feeling like there is no one to talk to about their struggles in their daily…
Homepage | Trauma Surgery & Acute Care Open
TSACO is an open access journal publishing high-quality epidemiological, educational, and socioeconomic research on trauma surgery and critical care.
Med School Malaise
Despite the record amount of money Americans spend on health care, statistics show we’re sicker, dying sooner, and seeing an explosion in chronic diseases…
Rush joins MD Anderson network of clinically affiliated systems
Patients at some Rush University System for Health locations will have access to MD Anderson’s clinical trials and network of specialists.
Myeloma Paper of the Day, April 26th, suggested by Robert Orlowski – OncoDaily
Myeloma Paper of the Day, April 26th, suggested by Robert Orlowski / AL Amyloidosis, amyloidosis, blood advances, cancer, CHIP, clonal hematopoiesis, Clonal
What Are the Benefits of Myeloma Consults and Second Opinions? – Patient Empowerment Network
What can myeloma consults and second opinions bring to patients? Dr. Ola Landgren shares his perspective on the benefits.
Restoring sight is possible now with optogenetics
Several companies are experimenting with optogenetics to create a “bionic eye” that can restore sight in visually impaired people.
